Advertisement
Screener

NEPHROS, INC. (NEPH) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 50/90 Roast Me

NEPHROS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

NEPHROS, INC. (NEPH) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-10

  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $1.20M, a 405.06% increase year-over-year.
  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $140.00K, a 74.91% decline year-over-year.
  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $62.00K, a 82.23% decline year-over-year.
  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $337.00K, a 84.15% increase year-over-year.
  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was $1.19M, a 1513.51% increase from fiscal 2024.
  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $74.00K.
  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$1.57M.
  • NEPHROS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$4.28M.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month
2026-06-30$1.20M
10-Q · filed 2026-08-10
$1.34M
10-Q · filed 2026-08-10
$1.40M
derived: sum of 3 quarters · filed 2026-08-10
$1.74M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$140.00K
10-Q · filed 2026-05-07
$202.00K
derived: sum of 2 quarters · filed 2026-05-07
$539.00K
derived: sum of 3 quarters · filed 2026-05-07
$776.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$62.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$399.00K
derived: sum of 2 quarters · filed 2026-03-12
$636.00K
derived: sum of 3 quarters · filed 2026-08-10
$1.19M
10-K · filed 2026-03-12
2025-09-30$337.00K
10-Q · filed 2025-11-06
$574.00K
derived: sum of 2 quarters · filed 2026-08-10
$1.13M
10-Q · filed 2025-11-06
$1.48M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$237.00K
10-Q · filed 2026-08-10
$795.00K
10-Q · filed 2026-08-10
$1.14M
derived: sum of 3 quarters · filed 2026-08-10
$1.33M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$558.00K
10-Q · filed 2026-05-07
$907.00K
derived: sum of 2 quarters · filed 2026-05-07
$1.09M
derived: sum of 3 quarters · filed 2026-05-07
$801.00K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$349.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$532.00K
derived: sum of 2 quarters · filed 2026-03-12
$243.00K
derived: sum of 3 quarters · filed 2026-03-12
$74.00K
10-K · filed 2026-03-12
2024-09-30$183.00K
10-Q · filed 2025-11-06
-$106.00K
derived: sum of 2 quarters · filed 2025-11-06
-$275.00K
10-Q · filed 2025-11-06
-$929.00K
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$289.00K
10-Q · filed 2025-08-07
-$458.00K
10-Q · filed 2025-08-07
-$1.11M
derived: sum of 3 quarters · filed 2025-08-07
-$1.29M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$169.00K
10-Q · filed 2025-05-15
-$823.00K
derived: sum of 2 quarters · filed 2025-05-15
-$1.00M
derived: sum of 3 quarters · filed 2025-05-15
-$1.44M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$654.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24
-$836.00K
derived: sum of 2 quarters · filed 2025-03-24
-$1.27M
derived: sum of 3 quarters · filed 2025-03-24
-$1.57M
10-K · filed 2025-03-24
2023-09-30-$182.00K
10-Q · filed 2023-11-08
-$615.00K
derived: sum of 2 quarters · filed 2023-11-08
-$921.00K
10-Q · filed 2023-11-08
-$1.64M
derived: sum of 4 quarters · filed 2024-03-15
2023-06-30-$433.00K
10-Q · filed 2023-08-09
-$739.00K
10-Q · filed 2023-08-09
-$1.46M
derived: sum of 3 quarters · filed 2024-03-15
-$2.71M
derived: sum of 4 quarters · filed 2024-03-15
2023-03-31-$306.00K
10-Q · filed 2023-05-10
-$1.02M
derived: sum of 2 quarters · filed 2024-03-15
-$2.27M
derived: sum of 3 quarters · filed 2024-03-15
-$3.02M
derived: sum of 4 quarters · filed 2024-03-15
2022-12-31-$719.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15
-$1.97M
derived: sum of 2 quarters · filed 2024-03-15
-$2.72M
derived: sum of 3 quarters · filed 2024-03-15
-$4.28M
10-K · filed 2024-03-15
2022-09-30-$1.25M
10-Q · filed 2023-11-08
-$2.00M
derived: sum of 2 quarters · filed 2023-11-08
-$3.56M
10-Q · filed 2023-11-08
-$4.28M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30-$747.00K
10-Q · filed 2023-08-09
-$2.31M
10-Q · filed 2023-08-09
-$3.03M
derived: sum of 3 quarters · filed 2023-08-09
-$3.83M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$1.56M
10-Q · filed 2023-05-10
-$2.29M
derived: sum of 2 quarters · filed 2023-05-10
-$3.09M
derived: sum of 3 quarters · filed 2023-05-10
2021-12-31-$725.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
-$1.53M
derived: sum of 2 quarters · filed 2023-03-23
-$2.78M
10-K · filed 2023-03-23
2021-09-30-$802.00K
10-Q · filed 2022-11-15
-$2.06M
10-Q · filed 2022-11-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sensus Healthcare, Inc. (SRTS)United States$0.048B-3.24
SANUWAVE Health, Inc. (SNWV)United States$0.041B5.47
Spectral AI, Inc. (MDAI)United States$0.052B
Xtant Medical Holdings, Inc. (XTNT)United States$0.053B
TELA Bio, Inc. (TELA)United States$0.057B-0.82
InspireMD, Inc. (NSPR)$0.033B
PAVmed Inc. (PAVM)United States$0.031B-3.00
Glucotrack, Inc. (GCTK)United States$0.027B
ACCURAY INC (ARAY)United States$0.027B-0.63
DarioHealth Corp. (DRIO)$0.066B-1.39